BCTXL · BriaCell Therapeutics Corp. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $25.81M | $21.27M | $27.18M | $15.34M | $8.02M | $2.02M | $2.43M | |
| — | $15.27K | $15.27K | $15.27K | $15.27K | $15.26K | — | |
| — | — | — | — | $15.27K | $15.26K | $15.26K | |
| $32.03M | $27.2M | $33.33M | $23.27M | — | — | — | |
| — | $36.98K | — | — | $979 | $78.55K | — | |
| $406.78K | $119.96K | $288.02K | $891.21K | $136.73K | $3149 | — | |
| $475.41K | $114.51K | $262.57K | $850.34K | -$11.55M | -$6.84M | — | |
| -$218.5K | -$224.21K | -$106.51K | — | — | — | — | |
| — | $26.56M | $4.93M | $20.3M | -$26.84M | -$13.82M | — | |
| — | — | — | — | $0 | — | — | |
| -$301.12K | -$244.27K | -$140.08K | — | — | — | — | |
| — | -$26.31M | -$4.79M | -$20.3M | -$26.84M | -$13.82M | — | |
| USD/shares | $2.29 | -$62.19 | -$43.68 | -$13.00 | -$17.30 | -$30.60 | — |
| USD/shares | $2.29 | -$62.19 | -$43.68 | -$13.00 | -$17.30 | — | — |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | 451.96K | — |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | — | — |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current unsecured bank loans received, including current portion of noncurrent unsecured bank loans | 2020-07-31 | CAD 306,878 | 40-F/A filed 2021-11-16 |
| Current unsecured bank loans received, including current portion of noncurrent unsecured bank loans | 2020-07-31 | USD 249,799 | 40-F/A filed 2021-11-16 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.